Clinical Trials Browser

Phase 2 × Mesothelioma, Malignant × atezolizumab × Clear all

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT04480372 2024-07-01

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Phase 2 Completed

68 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT03654833 2023-03-14

MiST

Phase 2 Unknown

186 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03786419 2021-05-13

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Phase 2 Withdrawn

Other solid neoplasmThoracic

Mesothelioma, Malignant, Thoracic Neoplasms

Clinical Trials

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

MiST

Immunological Variables Associated to ICI Toxicity in Cancer Patients

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma